Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
In This Article:
Biohaven stock tumbled for the second day running Tuesday after its bipolar mania treatment failed in a three-week study.
Oops, something went wrong
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Biohaven stock tumbled for the second day running Tuesday after its bipolar mania treatment failed in a three-week study.